Paul Biondi - Seres Therapeutics Independent Director
| 1S9 Stock | EUR 0.84 0.01 1.20% |
Director
Paul Biondi is Independent Director of Seres Therapeutics since 2020.
| Age | 50 |
| Tenure | 4 years |
| Phone | 617 945 9626 |
| Web | https://www.serestherapeutics.com |
Seres Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4018) % which means that it has lost $0.4018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.9017) %, meaning that it generated substantial loss on money invested by shareholders. Seres Therapeutics' management efficiency ratios could be used to measure how well Seres Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Cahill | American Airlines Group | 61 | |
| Georgios Vasilakis | AEGEAN AIRLINES | 47 | |
| Gregory Kerley | Southwest Airlines Co | 63 | |
| Jeffrey Benjamin | American Airlines Group | 58 | |
| Jon Marshall | Southwest Airlines Co | 67 | |
| Christos Ioannou | AEGEAN AIRLINES | 47 | |
| Patrick Prevost | Southwest Airlines Co | 63 | |
| Ray Robinson | American Airlines Group | 71 | |
| Martin Nesbitt | American Airlines Group | 56 | |
| Denise OLeary | American Airlines Group | 61 | |
| John Gass | Southwest Airlines Co | 67 | |
| Alexandros Makridis | AEGEAN AIRLINES | 57 | |
| James Albaugh | American Airlines Group | 68 | |
| Matthew Hart | American Airlines Group | 67 | |
| Susan Kronick | American Airlines Group | 67 | |
| Michael Embler | American Airlines Group | 55 | |
| Anne Taylor | Southwest Airlines Co | 63 | |
| Denis Walsh | Southwest Airlines Co | 58 | |
| Vittorio Pisante | AEGEAN AIRLINES | 54 | |
| NikolaosGeorgios Nanopoulos | AEGEAN AIRLINES | N/A | |
| Panagiotis Laskaridis | AEGEAN AIRLINES | N/A | |
Management Performance
| Return On Equity | -1.9 | |||
| Return On Asset | -0.4 |
Seres Therapeutics Leadership Team
Elected by the shareholders, the Seres Therapeutics' board of directors comprises two types of representatives: Seres Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seres. The board's role is to monitor Seres Therapeutics' management team and ensure that shareholders' interests are well served. Seres Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seres Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff York, VP HR | ||
| SPHR SHRMSCP, Ex Officer | ||
| Thomas DesRosier, Chief Legal Officer, Executive Vice President and Secretary | ||
| David Ege, Executive Vice President, Chief Technology Officer | ||
| Dennis Ausiello, Independent Director | ||
| Willard Dere, Independent Director | ||
| Eric Shaff, President, Chief Executive Officer, Director | ||
| David MBA, CFO VP | ||
| Carlo Tanzi, Head of Investor Relations and Corporate Communications | ||
| Kristin Ainsworth, Sr Communications | ||
| Marcus Chapman, Senior Vice President - Finance and Principal Financial and Accounting Officer | ||
| JD Esq, Exec Officer | ||
| Richard Kender, Independent Director | ||
| Lisa MD, Ex Officer | ||
| Meryl Zausner, Independent Director | ||
| Stephen Berenson, Independent Chairman of the Board | ||
| John Aunins, Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer | ||
| Matthew Henn, Executive Vice President Chief Scientific Officer | ||
| Jayne Gansler, Chief People Officer, Executive Vice President | ||
| Kurt Graves, Independent Director | ||
| Eric MBA, CEO Pres | ||
| Gregory Behar, Independent Director | ||
| Lisa Moltke, Executive Vice President Chief Medical Officer | ||
| Paul Biondi, Independent Director | ||
| Terri Young, Executive Vice President Chief Commercial and Strategy Officer |
Seres Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seres Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.9 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (17.02) % | |||
| Current Valuation | 582.79 M | |||
| Shares Outstanding | 124.59 M | |||
| Shares Owned By Insiders | 6.66 % | |||
| Shares Owned By Institutions | 85.90 % | |||
| Price To Book | 12.02 X | |||
| Price To Sales | 50.23 X | |||
| Revenue | 144.93 M |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.